Upcoming event

From October 15 to October 19, Radboud translational medicine will attend the 29th annual congress of the European Association of Nuclear Medicine.
Visit us at booth #59!

Other news

First Patient Dosed with TLX250-CDx in Italy for ccRCC

The below product is manufactured at RTM First Patient dosed with TLX250-CDx in Italy for ccRCC Th...

ABX has received marketing authorisation for the radiotracer Radelumin® in Germany

ABX has received marketing authorisation for the radiotracer Radelumin® in Germany! This marks the 8...

RTM receives marketing authorisation for Fludeoxyglucose (18F)

We are happy to announce that RTM has received marketing authorization for 18F-FDG of 17 July 2018....

LinkedIn post ESRR2024

📢 Important update on EU #GMP Annex 1 at #ESRR2024!  The revised EU GMP Annex 1, effecti...

News